Answers are grounded in this paper and cite their sources.
• Developed AAV-mediated CRISPR-Cas9 targeting conserved regions across HBV genotypes • Newly designed HBV-specific guide RNAs (gRNAs) with minimal off-target effects • gRNA2 induced frameshift mutations, significantly disrupting HBV gene function • gRNA2 outperformed RT gRNA and TAF, reducing HBV DNA, HBV RNA, cccDNA, and HBsAg • gRNA2 showed sustained antiviral effects, a promising chronic HBV therapy candidate Chronic hepatitis B virus (HBV) infection remains a major global health burden due to the persistence of covalently closed circular DNA (cccDNA), which limits current antiviral therapies. We developed an adeno-associated virus (AAV)-delivered CRISPR/Cas9 system targeting conserved regions of the HBV genome. Three guide RNAs (gRNA1–3) targeting overlapping open reading frames of the surface antigen and polymerase genes were evaluated in HepG2.2.15 cells and inducible HBV-infected human hepatocyte-like cells (d-imHCs), with a reverse transcriptase-targeting gRNA and tenofovir alafenamide as controls. All gRNAs significantly reduced intracellular and extracellular HBV DNA and moderately decreased HBsAg secretion. Notably, gRNA2 induced a frameshift mutation and demonstrated superior antiviral efficacy, markedly reducing cccDNA, viral DNA, viral RNA, HBcAg, and HBsAg secretion with sustained suppression for up to 12 days. These findings highlight AAV-mediated CRISPR/Cas9 as a promising gene-based therapy for chronic HBV infection.
No takes yet. Share an insight, caveat, or question.
Kongsomboonchoke et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: